<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="97534">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02017457</url>
  </required_header>
  <id_info>
    <org_study_id>BHS-TC-10</org_study_id>
    <nct_id>NCT02017457</nct_id>
  </id_info>
  <brief_title>Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation.</brief_title>
  <official_title>Sequential Administration of 5-azacytidine (AZA) and Donor Lymphocyte Infusion (DLI) for Patients With Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) in Relapse After Allogeneic Stem Cell Transplantation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carlos Graux, MD, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Europe Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Belgian Hematological Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital of Mont-Godinne</source>
  <oversight_info>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present project is a multicenter, phase II trial which aims at evaluating if the
      administration of azacytidine (Vidaza®) combined to donor lymphocyte infusion (DLI) could
      improve the response rate to DLI in the population of patients with relapsed acute myeloid
      leukemia (AML) and myelodysplastic syndrome  (MDS) after allogeneic hematopoietic stem cell
      transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>Will be evaluated at day 24 of cycle 1, 3 and 5. Then every 3 months for a year after cycle 6 thereafter at 1.5 and 2 years after cycle 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>To assess the response rate to DLI by the combination with azacytidine in the population of patients with relapsed AML and MDS after allo-SCT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>2 years after cycle 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years after cycle 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>At the beginning of each cycle and at the discretion of the investigator until cycle 6, then monthly for 6 months, thereafter every 3 months for 1.5 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Evaluate haematological and non-haematological toxicities and safety of the planned therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of GvHD</measure>
    <time_frame>At the beginning of each cycle and at the discretion of the investigator until cycle 6, then monthly for 6 months, thereafter every 3 months for 1.5 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of infections</measure>
    <time_frame>At the beginning of each cycle and at the discretion of the investigator until cycle 6, then monthly for 6 months, thereafter every 3 months for 1.5 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Immune reconstitution</measure>
    <time_frame>On day 1 of each cycle until cycle 6, then every 3 months for a year and at 1.5 and 2 years after cycle 6</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Treg expansion</measure>
    <time_frame>On day 1 of each cycle until cycle 6, then every 3 months for a year and at 1.5 and 2 years after cycle 6</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Acute Myelogenous Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>Azacytidine + Donor lymphocyte infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Azacytidine will be administered subcutaneously for 5 days. During the first cycle, a dose of 100mg/m2/day will be used and for the following cycles a dose of 35mg/m2/day will be administered. Each cycle will consist in 28 days. All patients will receive at least 6 cycles of Azacytidine and the total number of cycles will depend on the response to treatment.
Donor lymphocyte infusion will be performed on day 1 of cycle 2, 4 and 6 of Azacytidine. The amount of cells infused will depend on donor origin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Donor lymphocyte infusion</intervention_name>
    <description>On day 1 of cycle 2, 4 and 6 of Azacytidine, patients will be infused with donor lymphocytes.
Patients with a sibling donor will receive:
1x10exp7 CD3+/kg on day 1 of cycle 2
5x10exp7 CD3+/kg on day 1 of cycle 4
1x10exp8 CD3+/kg on day 1 of cycle 6
Patients with an unrelated donor will receive:
1x10exp6 CD3+/kg on day 1 of cycle 2
5x10exp6 CD3+/kg on day 1 of cycle 4
1x10exp7 CD3+/kg on day 1 of cycle 6</description>
    <arm_group_label>Azacytidine + Donor lymphocyte infusion</arm_group_label>
    <other_name>DLI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacytidine</intervention_name>
    <description>Cycle 1: Subcutaneous administration of 100mg/m2/day for 5 days.
Cycle 2: Subcutaneous administration of 35mg/m2/day for 5 days. Cycles will be administered every 28 days.
All patients will receive at least 6 cycles of Azacytidine. In case of complete remission after cycle 5, 2 additionnal cycles will be administered after achievement of complete remission.
In case of stable disease or partial response, Azacytidine will be continued until progression.
In case of disease progression after cycle 6, Azacytidine will be stopped.</description>
    <arm_group_label>Azacytidine + Donor lymphocyte infusion</arm_group_label>
    <other_name>Vidaza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients:

               -  Age ≥ 18 years

               -  Be able to understand and sign informed consent

               -  Fertile patients must use a reliable contraception method

          2. Disease status at transplantation:

               -  AML in first or subsequent complete remission (&lt; 5% marrow blasts)

               -  MDS with less than 10% marrow blasts at the time of transplantation

          3. Transplantation:

               -  Allogeneic transplantation using a sibling or unrelated donor with   matching in
                  10/10 alleles (HLA-A, B, C, DRB1, DQB1) or maximum of one allele or one antigen
                  or 1 antigen + 1 allele or 1 antigen + 1 DQB1 antigen or 2 alleles mismatches.

               -  Myeloablative or reduced-intensity conditioning

               -  Second transplantation is allowed

               -  Donor is willing to donate lymphocytes

          4. Clinical situation:

               -  Cytological relapse after allo-SCT defined as the recurrence of more than 5%
                  blasts on bone marrow aspiration (AML) or evidence of MDS

               -  Immunophenotypic relapse defined as the recurrence of an abnormal phenotype on
                  flow cytometry in bone marrow aspirate (only in case of a specific phenotype).

               -  Cytogenetic or molecular relapse defined as the persistence or recurrence of a
                  cytogenetic abnormality or molecular marker in bone marrow aspiration or
                  peripheral blood. WT1 expression is not considered as reliable marker for
                  relapse in this protocol but FLT3-ITD, NPM1, CEBPA, or translocation-specific
                  markers (such as MLL-PTD, AML-ETO, CBFB-MYH11) are.

          5. Immunosuppressive therapy should have been withdrawn in the month preceding inclusion

        Exclusion Criteria:

          -  More than 30% marrow blasts at the time of inclusion

          -  Extramedullary relapse including CNS involvement

          -  ECOG Performance status &gt; 2

          -  Active acute grade II-IV GvHD at the time of inclusion

          -  Active chronic GvHD requiring systemic therapy at the time of inclusion

          -  Uncontrolled infection

          -  HIV positive

          -  Acute or chronic heart failure (NYHA class III or IV) or symptomatic ischemic heart
             disease or ejection fraction &lt; 35% or uncontrolled arrhythmia

          -  Severe liver failure (total bilirubin &gt; 3 mg/dL, SGPT &gt; 4 X upper normal limit)

          -  Severe pulmonary failure (corrected DLCo &lt; 35%)

          -  Terminal renal failure requiring dialysis

          -  Severe neurological or psychiatric disorders

          -  Concurrent investigational drug.

          -  Other treatment for relapse, except for hydroxyurea.

          -  Female who is pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xavier Poiré, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliniques universitaires Saint-Luc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos Graux, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliniques Universitaires Mont-Godinne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xavier Poiré, MD</last_name>
    <phone>32-2-7641809</phone>
    <email>Xavier.Poire@uclouvain.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carlos Graux, MD,PhD</last_name>
    <phone>32-81-423831</phone>
    <email>Carlos.Graux@uclouvain.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ziekenhuis Netwerk Antwerpen</name>
      <address>
        <city>Antwerpen</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Zachee, MD, PhD</last_name>
      <phone>32-3-2177111</phone>
      <email>pierre.zachee@zna.be</email>
    </contact>
    <investigator>
      <last_name>Pierre Zachee, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Jan Brugge</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominik Selleslag, MD</last_name>
      <phone>32-50-453060</phone>
      <email>dominik.selleslag@azbrugge.be</email>
    </contact>
    <contact_backup>
      <last_name>Tom Lodewyck, MD</last_name>
      <phone>32-50-453060</phone>
      <email>tom.lodewyck@azbrugge.be</email>
    </contact_backup>
    <investigator>
      <last_name>Dominik Selleslag, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tom Lodewyck, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Lewalle, MD, PhD</last_name>
      <phone>32-2-5417208</phone>
      <email>philippe.lewalle@bordet.be</email>
    </contact>
    <investigator>
      <last_name>Philippe Lewalle, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zwi Berneman, MD, PhD</last_name>
      <phone>32-3-2204111</phone>
      <email>zwi.berneman@uza.be</email>
    </contact>
    <investigator>
      <last_name>Zwi Berneman, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucien Noens, MD, PhD</last_name>
      <phone>32-9-3323464</phone>
      <email>Lucien.Noens@Ugent.be</email>
    </contact>
    <contact_backup>
      <last_name>Tessa Kerre, MD, PhD</last_name>
      <phone>32-9-3323464</phone>
      <email>Tessa.Kerre@Ugent.be</email>
    </contact_backup>
    <investigator>
      <last_name>Lucien Noens, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tessa Kerre, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital de Jolimont</name>
      <address>
        <city>Haine-St-Paul</city>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Straetmans, MD, PhD</last_name>
      <phone>32-64-233989</phone>
      <email>nicoles.Straetmans@scarlet.be</email>
    </contact>
    <investigator>
      <last_name>Nicole Straetmans, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Brussel</name>
      <address>
        <city>Jette</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rik Schots, MD, PhD</last_name>
      <phone>32-2-4763105</phone>
      <email>Rik.Schots@uzbrussel.be</email>
    </contact>
    <contact_backup>
      <last_name>Ann De Becker, MD</last_name>
      <phone>32-2-4763105</phone>
      <email>Ann.Debecker@uzbrussel.be</email>
    </contact_backup>
    <investigator>
      <last_name>Rik Schots, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ann De Becker, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johan Maertens, MD,PhD</last_name>
      <phone>32-16-332211</phone>
      <email>Johan.Maetens@uzleuven.be</email>
    </contact>
    <contact_backup>
      <last_name>Hélène Schoemans, MD</last_name>
      <phone>32-16-332211</phone>
      <email>Helene.Schoemans@uzleuven.be</email>
    </contact_backup>
    <investigator>
      <last_name>Johan Maertens, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hélène Schoemans, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Liège</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yves Beguin, MD, PhD</last_name>
      <phone>32-4-3667201</phone>
      <email>yves.beguin@chu.ulg.ac.be</email>
    </contact>
    <contact_backup>
      <last_name>Frédéric Baron, MD, PhD</last_name>
      <phone>32-4-3667201</phone>
      <email>F.Baron@ulg.ac.be</email>
    </contact_backup>
    <investigator>
      <last_name>Yves Beguin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frédéric Baron, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Evelyne Willems, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hartziekenhuis Roeselare Menen</name>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dries Deeren, MD</last_name>
      <phone>32-51-237437</phone>
      <email>ddeeren@hhr.be</email>
    </contact>
    <investigator>
      <last_name>Dries Deeren, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Woluwe-Saint-Lambert</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier Poiré, MD</last_name>
      <phone>32-2-7641809</phone>
      <email>Xavier.Poire@uclouvain.be</email>
    </contact>
    <investigator>
      <last_name>Xavier poiré, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Mont-Godinne</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Graux, MD,PhD</last_name>
      <phone>32-81-423831</phone>
      <email>Carlos.Graux@uclouvain.be</email>
    </contact>
    <investigator>
      <last_name>Carlos Graux, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 7, 2014</lastchanged_date>
  <firstreceived_date>December 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital of Mont-Godinne</investigator_affiliation>
    <investigator_full_name>Carlos Graux, MD, PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Hematology</keyword>
  <keyword>Acute Myelogenous Leukemia</keyword>
  <keyword>Myelodysplasic syndrome</keyword>
  <keyword>Allogeneic stem cell transplantation</keyword>
  <keyword>Donor lymphocyte infusion</keyword>
  <keyword>DLI</keyword>
  <keyword>Azacytidine</keyword>
  <keyword>Vidaza</keyword>
  <keyword>Overall response rate</keyword>
  <keyword>Relapse</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
